Who are %40 diluted Autologous serum's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Autologous serum, Autologous Serum 20%, Autologous Serum 50%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/40-diluted-autologous-serum.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

%40 diluted Autologous serum — Competitive Intelligence Brief

%40 diluted Autologous serum (%40 diluted Autologous serum) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Autologous biologic. Area: Ophthalmology.

marketed Autologous biologic Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

%40 diluted Autologous serum (%40 diluted Autologous serum) — Niğde State Hospital. Diluted autologous serum provides immunomodulatory and anti-inflammatory effects through patient-derived serum factors.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
%40 diluted Autologous serum TARGET	%40 diluted Autologous serum	Niğde State Hospital	marketed	Autologous biologic
Autologous serum	Autologous serum	Anita Syla Lokaj	marketed	Autologous biological product
Autologous Serum 20%	Autologous Serum 20%	Pontificia Universidad Catolica de Chile	phase 3	Autologous biological therapeutic
Autologous Serum 50%	Autologous Serum 50%	Pontificia Universidad Catolica de Chile	phase 3	Autologous biological preparation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Autologous biologic class)

Niğde State Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). %40 diluted Autologous serum — Competitive Intelligence Brief. https://druglandscape.com/ci/40-diluted-autologous-serum. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab